OncoMatch/Clinical Trials/NCT06667908
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
Is NCT06667908 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Durvalumab and JNJ-90301900 for carcinoma, non-small-cell lung.
Treatment: JNJ-90301900 · Durvalumab · Concurrent Chemo/Radiation Therapy (cCRT): Carboplatin · Concurrent Chemo/Radiation Therapy (cCRT): Paclitaxel — The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can improve objective response rate (ORR; that is percentage of participants whose best response is complete response or partial response during the study) in participants with locally advanced and unresectable stage III non-small cell lung cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Required: Stage III
Performance status
ECOG 0–1(Restricted strenuous activity)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Connecticut Health Center · Farmington, Connecticut
- Yale University · New Haven, Connecticut
- University of Miami · Miami, Florida
- Orlando Health Cancer Institute · Orlando, Florida
- Emory University Winship Cancer Institute · Atlanta, Georgia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify